Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of the U.S. financial ...
Zacks.com on MSN
HudBay Minerals (HBM) Earnings Expected to Grow: Should You Buy?
The market expects HudBay Minerals (HBM) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus ...
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on February 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to ten new employees, ...
Robbins Geller Rudman & Dowd LLP recently announced it is investigating potential violations of U.S. federal securities laws ...
Novartis to seek full FDA approval for IgAN drug Vanrafia despite missing ph. 3 kidney function goal
It’s déjà vu all over again. Just as the kidney disease space becomes increasingly competitive, Novartis has found itself intending to turn a statistical miss into a regulatory win. | It’s déjà vu all ...
Travere Therapeutics is focused on rare kidney diseases, with FILSPARI driving significant revenue growth in IgA Nephropathy (IgAN). Competition in IgAN from larger players like Novartis and Vertex is ...
Travere Therapeutics, Inc. today announced that company management will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 4:00 p.m. ET. A live webcast ...
The purchase of Travere Therapeutics shares by Palisades Investment Partners is noteworthy because it represented a new position for the investment firm. The transaction came in the fourth quarter of ...
Cineverse Corp. , an innovative and independent entertainment technology company and studio, today announced that on February ...
On the same dates, Dube exercised options to acquire 60,000 shares of Travere Therapeutics common stock at a price of $15.46, for a total value of $927600. In other recent news, Travere Therapeutics ...
BOSTON, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Travere Therapeutics, Inc. (Nasdaq: TVTX) for potential securities law violations. Investors who have lost money in their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results